SONN Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 2.00%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

Sonnet BioTherapeutics Insider Trading History Chart

Sonnet BioTherapeutics Share Price & Price History

^$4.33

▲ +0.01 (0.23%)

As of 11/4/2024 01:00 AM ET

Days: 30 | 90 | 365

Bill Gates’s Next Big AI Bet: Stargate

From Brownstone Research | Ad

In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.

I believe we are about to do it again with this new AI project called Stargate

Sonnet BioTherapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/14/2023	Susan Dexter	Insider	Buy	454	$15.40	$6,991.60	1,530
5/30/2023	Albert D Dyrness	Director	Buy	1,057	$10.34	$10,929.38	1,316
5/17/2023	Nailesh Bhatt	Director	Buy	1,136	$5.06	$5,748.16	1,396
5/15/2023	Pankaj Mohan	CEO	Buy	16,890	$4.84	$81,747.60	25,151

The most serious warning of my career

From Porter & Company | Ad

With the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the financial world in two the moment the polls close. I predict they could see investment losses of 50% (or more) in the weeks following the presidential election.

Click here now to grab your seat now.

SEC Filings (Institutional Ownership Changes) for Sonnet BioTherapeutics (NASDAQ:SONN)

9.45% of Sonnet BioTherapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Sonnet BioTherapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
8/15/2024	Armistice Capital LLC	272,000	$0.26M	0.0%	N/A	8.740%
7/27/2023	Virtu Financial LLC	86,624	$42K	0.0%	N/A	0.315%
5/19/2023	Anson Funds Management LP	1,760,000	$0.63M	0.1%	N/A	6.405%
11/7/2022	Virtu Financial LLC	26,914	$40K	0.0%	N/A	0.622%
8/2/2022	Advisory Services Network LLC	130,525	$37K	0.0%	+158.3%	0.215%
5/10/2022	Campion Asset Management	90,612	$34K	0.0%	N/A	0.150%
8/16/2021	State Street Corp	62,688	$99K	0.0%	N/A	0.253%
8/13/2021	Vanguard Group Inc.	701,634	$1.11M	0.0%	+416.0%	2.834%
5/19/2021	Virtu Financial LLC	65,106	$0.15M	0.0%	N/A	0.371%
5/18/2021	Citadel Advisors LLC	113,264	$0.26M	0.0%	N/A	0.534%
5/18/2021	Jane Street Group LLC	17,304	$39K	0.0%	N/A	0.099%
5/17/2021	Price T Rowe Associates Inc. MD	45,100	$0.10M	0.0%	N/A	0.257%
5/13/2021	Bank of New York Mellon Corp	20,399	$46K	0.0%	N/A	0.116%
5/7/2021	BlackRock Inc.	255,761	$0.58M	0.0%	+3.7%	1.457%
3/26/2021	Susquehanna International Group LLP	15,434	$34K	0.0%	N/A	0.088%
2/9/2021	Advisory Services Network LLC	24,581	$55K	0.0%	+32.3%	0.143%
2/5/2021	BlackRock Inc.	246,555	$0.55M	0.0%	+2.5%	1.435%
11/19/2020	Schonfeld Strategic Advisors LLC	12,200	$31K	0.0%	N/A	0.071%
11/19/2020	IHT Wealth Management LLC	10,000	$26K	0.0%	N/A	0.058%
11/17/2020	Schonfeld Strategic Advisors LLC	12,200	$31K	0.0%	N/A	0.089%

Data available starting January 2016

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.

Today's Range

Now: $4.33

$4.00

$4.33

50 Day Range

MA: $3.15

$0.71

$6.71

52 Week Range

Now: $4.33

$4.00

$18.72

Volume

17,005 shs

Average Volume

15,586 shs

Market Capitalization

$2.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.52

Who are the company insiders with the largest holdings of Sonnet BioTherapeutics?: Sonnet BioTherapeutics' top insider investors include:
Pankaj Mohan (CEO)
Susan Dexter (Insider)
Nailesh Bhatt (Director)
Albert D Dyrness (Director)
Learn More about top insider investors at Sonnet BioTherapeutics.